Objective: To clarify the actual situation about awareness of DI (the Drug Information in-charge) or information shared with the hospital including prescribing physician regarding the generics, which have added with other dosage innovators don’t have.
Methods: We did the questionnaire and analyzed awareness of DI, route of access to information, situation of transmission for the prescribing physician, and prescription regarding generics added with other dosage (Clopidogrel 50 mg, Quetiapine 12.5 mg, 50 mg, and Tacrolimus 1.5 mg, 3 mg).
Results: There were many cases that DI obtained the information regarding generics added with other dosage from MRs, magazine or website Web.  On the other hand, in case that conveys information about generics added with other dosage to the prescribing physician wasn’t so many.  And there were various reasons why the Drug Information in-charge didn’t inform to the prescribing physician.
Conclusion: Analysis of the valid responses was that more than two-thirds of DI recognized about generics added with other dosage of Clopidogrel and Quetiapine.  But share of recognition of DI was below 30% in case of Tacrolimus.  Also, share of transfer to the prescribing physician was about 15% in any case.  Main source of information about generics added with other dosage for DI was from MRs, magazine or website.  As the number of the companies which sell generics added with other dosage of Tacrolimus is few, we assumed that most of DI didn’t recognize it.  In addition, there were many comments which were judged that it isn’t necessary to transmit to the prescribing physician information generics added with other dosage in case of Clopidogrel and Quetiapine in the questionnaire.  On the other hand, though the number of sample was small compare to the case of Clopidogrel and Quetiapine, there was no comment that generics added with other dosage of Tacrolimus isn’t necessary.